Reich, K.; Simpson, E.; Langley, R.; Warren, R.; Costanzo, A. .; Saeki, H.; Almgren, P.; Gjerum, L.; Carlsson, A.; Gooderham, M.; Pinter, A.; De Bruin Weller, M.; Blauvelt, A. Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest. J of Skin 2023, 7, s143.